血脂康在老年高脂血症患者中的应用

Application of Xuezhikang in elderly hyperlipidemia patients

目的探讨使用血脂康治疗老年高脂血症患者的安全性及疗效。方法选择2017年9月~2018年10月在我院冠心病复查门诊就诊的老年高脂血症患者100例,随机分为对照组50例(阿托伐他汀20 mg,1次/晚),观察组50例(血脂康0.6 g,2次/d),治疗4周后,观察2组患者肝肾功能,肌酸激酶和血糖变化。结果治疗4周后,2组TC、LDL-C和TG水平较治疗前明显降低,其中观察组TC、LDL-C和TG水平较治疗前分别下降30.9%、28.2%和18.5%;对照组TC、LDL-C和TG水平较治疗前分别下降45.1%、40.5%和8.9%,均有统计学差异(P<0.05),治疗后观察组与对照组TC、TG和LDL-C水平比较,差异有统计学意义[(3.87±1.43)mmol/L vs(3.03±1.42)mmol/L,(1.20±0.31)mmol/L vs(1.38±0.39)mmol/L,(2.77±0.48)mmol/L vs(2.32±0.42)mmol/L,P<0.05]。2组治疗前后肌酐、丙氨酸转氨酶和肌酸激酶等比较,无显著差异(P>0.05)。结论老年高脂血症患者服用血脂康安全有效。

Objective To study the safety and efficacy of Xuezhikang(a blood-lipid lowering Chinese drug)in elderly hyperlipidemia patients.Methods One hundred elderly hyperlipidemia patients who visited the Outpatient Department of our hospital from Septembet 2017 to October 2018 were randomly divided into control group(n=50)and observation group(n=50).The serum levels of blood glucose and creatine kinase were measured,and the hepatic and renal functions were tested at week 4 after the patients in control group were treated with atorvastatin(20 mg,once a day)and those in observation group were treated with Xuezhikang(0.6 g,twice a day).After 4 weeks,the changes of lipid level,liver and kidney function,CK and FPG were observed in two groups.Results The serum levels of TC,LDL-C,and TG were significantly lower in two groups after 4 weeks of treatment than before treatment(P<0.05),which reduced 30.9%,28.2%and 18.5%respectively in observation group and 45.1%,40.5%and 8.9%respectively in control group after 4 weeks of treatment than before treatment.There was significant difference in the serum levels of TC,TG,LDL-C betwwen the two groups(3.87±1.43 mmol/L vs 3.03±1.42 mmol/L,1.20±0.31 mmol/L vs 1.38±0.39 mmol/L,2.77±0.48 mmol/L vs 2.32±0.42 mmol/L,P<0.05).No significant difference was detected in hepatic and renal functions and serum CK level between the two groups before and after treatment(P>0.05).Conclusion Xuezhikang is safe and effective for elderly hyperlipidemia patients.